KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Payables: 2010-2024

Historic Payables for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Dec 2024 value amounting to $3.3 million.

  • Rigel Pharmaceuticals' Payables rose 0.81% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year decrease of 30.10%. This contributed to the annual value of $3.3 million for FY2024, which is 53.25% down from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Payables of $3.3 million as of FY2024, which was down 53.25% from $7.1 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Payables ranged from a high of $22.5 million in FY2022 and a low of $3.3 million during FY2024.
  • In the last 3 years, Rigel Pharmaceuticals' Payables had a median value of $7.1 million in 2023 and averaged $11.0 million.
  • Its Payables has fluctuated over the past 5 years, first skyrocketed by 493.10% in 2022, then crashed by 68.27% in 2023.
  • Rigel Pharmaceuticals' Payables (Yearly) stood at $3.7 million in 2020, then increased by 2.37% to $3.8 million in 2021, then surged by 493.10% to $22.5 million in 2022, then tumbled by 68.27% to $7.1 million in 2023, then tumbled by 53.25% to $3.3 million in 2024.